Purpose and Scope of PPG

This guideline provides clinicians with information to support and manage women with epilepsy before pregnancy and throughout the perinatal period. It includes specific information on epilepsy medication and adjunctive therapies such as folate and vitamin K. Neonatal and breastfeeding considerations are also identified.

Australian Aboriginal Culture is the oldest living culture in the world yet Aboriginal people continue to experience the poorest health outcomes when compared to non-Aboriginal Australians. In South Australia, Aboriginal women are 2-5 times more likely to die in childbirth and their babies are 2-3 times more likely to be of low birth weight. The accumulative effects of stress, low socio economic status, exposure to violence, historical trauma, culturally unsafe and discriminatory health services and health systems are all major contributors to the disparities in Aboriginal maternal and birthing outcomes. Despite these unacceptable statistics the birth of an Aboriginal baby is a celebration of life and an important cultural event bringing family together in celebration, obligation and responsibility. The diversity between Aboriginal cultures, language and practices differ greatly and so it is imperative that perinatal services prepare to respectively manage Aboriginal protocol and provide a culturally positive health care experience for Aboriginal people to ensure the best maternal, neonatal and child health outcomes.
Table I: Classification of epileptic seizures according to clinical type

<table>
<thead>
<tr>
<th>Partial (focal, local) seizures</th>
<th>Simple partial seizures (SPS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Temporal lobe SPS</strong></td>
<td>Symptoms can include:</td>
</tr>
<tr>
<td>are the most common</td>
<td>➢ An ‘epigastric rising sensation’</td>
</tr>
<tr>
<td>type of SPS</td>
<td>➢ Déjà vu (the feeling of ‘having been here before’) or jamais vu (where familiar things seem new)</td>
</tr>
<tr>
<td></td>
<td>➢ A flashback of memory</td>
</tr>
<tr>
<td></td>
<td>➢ A sudden, intense feeling of fear or joy</td>
</tr>
<tr>
<td></td>
<td>➢ A funny taste or smell</td>
</tr>
<tr>
<td><strong>Frontal lobe SPS</strong></td>
<td>Some people experience:</td>
</tr>
<tr>
<td>can be harder to describe</td>
<td>➢ Strange movements</td>
</tr>
<tr>
<td></td>
<td>➢ A feeling of a wave going through the head or body</td>
</tr>
<tr>
<td></td>
<td>➢ Stiffness or jerking of part of the body that might start in one place, for example the face, and spread to other parts of the body</td>
</tr>
<tr>
<td><strong>Parietal lobe SPS</strong></td>
<td>Often include strange sensations such as:</td>
</tr>
<tr>
<td></td>
<td>➢ Numbness or tingling</td>
</tr>
<tr>
<td></td>
<td>➢ Burning sensations or a feeling of heat</td>
</tr>
<tr>
<td></td>
<td>➢ A feeling that part of the body, an arm or leg, is bigger or smaller than they really are</td>
</tr>
<tr>
<td><strong>Occipital lobe SPS</strong></td>
<td>Involve visual sensations, such as:</td>
</tr>
<tr>
<td></td>
<td>➢ Distortion or loss of vision</td>
</tr>
<tr>
<td></td>
<td>➢ Seeing flashing lights or coloured shapes</td>
</tr>
<tr>
<td></td>
<td>➢ Seeing people or objects that are not there (hallucinations)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complex partial seizures (CPS)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Temporal lobe CPS</strong></td>
<td>Most common CPS</td>
</tr>
<tr>
<td></td>
<td>➢ Automatisms such as lip-smacking or chewing movements, or rubbing, stroking or fiddling with their hands;</td>
</tr>
<tr>
<td></td>
<td>➢ Or looking from one side to another in a confused way</td>
</tr>
<tr>
<td><strong>Frontal lobe CPS</strong></td>
<td>Often much shorter than temporal lobe CPS, usually lasting about 15-30 seconds:</td>
</tr>
<tr>
<td></td>
<td>➢ Make strange postures with their arms or legs; or</td>
</tr>
<tr>
<td></td>
<td>➢ Make juddering movements</td>
</tr>
</tbody>
</table>
Table I continued: Classification of epileptic seizures according to clinical type

<table>
<thead>
<tr>
<th>Type of Seizure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generalised seizures (convulsive or non convulsive)</strong></td>
<td></td>
</tr>
<tr>
<td>Tonic-clonic seizures</td>
<td>Tonic–clonic seizures involve a tonic phase, in which the muscles suddenly contract, causing the person to fall and lie rigid. Up to a minute later, the seizure enters the clonic phase, when the muscles begin to alternate between relaxation and rigidity. The person may lose bowel or bladder control. The seizure usually lasts for 2–3 minutes, after which the person remains unconscious for a while. On waking, the person is likely to have a headache and to be confused and tired.</td>
</tr>
<tr>
<td>Clonic seizures</td>
<td>A series of myoclonic contractions that regularly recur at a rate of 0.2 – 5/second</td>
</tr>
<tr>
<td>Atonic seizures</td>
<td>Cause a loss of postural tone. The result is loss of posture (head drops, falls) and are often preceded by a short myoclonic seizure</td>
</tr>
<tr>
<td>Myoclonic seizures</td>
<td>Short muscle contractions, usually lasting &lt; 400 milliseconds</td>
</tr>
<tr>
<td>Absence seizures</td>
<td>Impairment of consciousness alone or with: mild clonic, atonic or tonic components, automatisms and/or autoimmune symptoms or signs</td>
</tr>
<tr>
<td><strong>Secondarily generalized seizures</strong></td>
<td></td>
</tr>
<tr>
<td>Partial seizures evolving to secondary generalized seizures (may be generalized tonic-clonic, tonic or clonic)</td>
<td>SPS evolving to generalized seizures</td>
</tr>
<tr>
<td></td>
<td>CPS evolving to generalized seizures</td>
</tr>
<tr>
<td></td>
<td>SPS evolving to CPS and then evolving to generalized seizures</td>
</tr>
<tr>
<td><strong>Unclassified seizures</strong></td>
<td></td>
</tr>
</tbody>
</table>

Table of Contents

Purpose and Scope of PPG
Table I: Classification of epileptic seizures according to clinical type
Summary of Practice Recommendations
Abbreviations
Epilepsy
Literature review
Pre-pregnancy care
  Contraception
  Conception
  Pregnancy
Antiepileptic drugs (AEDs)
  Phenytoin
  Carbamazepine
  Sodium valproate
  Phenobarbital and Primidone
  Lamotrigine
Management
  Antenatal
    Vitamin K
  Intrapartum
    Immediately following birth
Postpartum
  Antiepileptic drugs
  Newborn care
  Breastfeeding
  Contraception
  Discharge counselling
  Follow-up
References
Acknowledgements
Summary of Practice Recommendations

Pre-pregnancy counselling should provide a clear understanding of the risks of uncontrolled seizures and the possible teratogenicity of anticonvulsant agents.

Most women with epilepsy will need to continue taking antiepileptic drugs in pregnancy.

The treatment goal in pregnancy is to maintain a balance between an effective but low dose of a single antiepileptic drug and the harmful effects of seizures.

For women taking sodium valproate pre-pregnancy, consideration should be given to a suitable alternative agent if appropriate.

High dose folic acid is recommended for women taking antiepileptic medication 1 month before conception and in the first trimester.

Review by a neurologist or specialist physician should occur in the first trimester.

Simple partial, complex partial, absence and myoclonic seizures do not affect the pregnancy or developing fetus adversely unless women fall and sustain an injury.

Detailed morphology USS at 18 – 20 weeks gestation is required. Ensure the request form includes details of all antiepileptic medication.

Consider antenatal prophylaxis with oral vitamin K1 20 mg per day in the last 4 weeks of pregnancy if enzyme-inducing drugs are used.

Two to four percent of women with epilepsy will have a tonic-clonic seizure during labour or in the first 24 hours after labour which may result in fetal hypoxia.

Continue oral anticonvulsants in labour.

Ensure intravenous access in labour.

If the mother is using antiepileptic drugs that are associated with drowsiness, monitor the breastfed baby for prolonged sedation, disinterest in feeding and inadequate weight gain.

The oral progestogen-only pill or progesterone implant (Implanon®) is unreliable contraception for women on the enzyme-inducing anticonvulsants.

Offer advice to women at risk of further seizure activity to minimise any injury risk to baby.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADEC</td>
<td>Australian Drug Evaluation Committee</td>
</tr>
<tr>
<td>AEDs</td>
<td>Anti-epileptic drugs</td>
</tr>
<tr>
<td>AMH</td>
<td>Australian Medicines Handbook</td>
</tr>
<tr>
<td>Cat</td>
<td>Category</td>
</tr>
<tr>
<td>CPS</td>
<td>Complex partial seizures</td>
</tr>
<tr>
<td>CYWHS</td>
<td>Children Youth and Women’s Health Service</td>
</tr>
<tr>
<td>e.g.</td>
<td>For example</td>
</tr>
<tr>
<td>Et al.</td>
<td>And others</td>
</tr>
<tr>
<td>FHS</td>
<td>Fetal Hydantoin Syndrome</td>
</tr>
<tr>
<td>IQ</td>
<td>Intelligence Quotient</td>
</tr>
<tr>
<td>IUD</td>
<td>Intrauterine device</td>
</tr>
<tr>
<td>Kg</td>
<td>Kilograms(s)</td>
</tr>
<tr>
<td>Mg</td>
<td>Milligram(s)</td>
</tr>
<tr>
<td>SPS</td>
<td>Simple partial seizures</td>
</tr>
<tr>
<td>TGA</td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td>WCHN</td>
<td>Women’s and Children’s Hospital Network</td>
</tr>
</tbody>
</table>
Epilepsy and pregnancy management

Epilepsy

> Epilepsy is a common neurological condition characterised by seizures
> Epileptic seizures are caused by paroxysmal discharges of excessive and/or hyper-synchronous abnormal activity of cerebral cortical neurones
> Drug use to control epilepsy in the population ranges from 4 to 9 per 1,000
> Most women with epilepsy will need to continue taking antiepileptic drugs in pregnancy to prevent the harmful effects of seizures
> The treatment goal in pregnancy is to maintain a balance between an effective but low dose of a single antiepileptic drug and the harmful effects of seizures

Literature review

> In Australia, approximately 1,500 to 2,000 women on antiepileptic drugs become pregnant per year
> Retrospective studies report a 2- to 3-fold increase in adverse pregnancy outcomes for women on antiepileptic drugs. These include:
  > Miscarriage
  > Major congenital malformations (neural tube defects, orofacial defects, congenital heart abnormalities and hypospadias)
  > Minor congenital anomalies (hypertelorism, epicanthic folds and digital hypoplasia)
  > Microcephaly
  > Intrauterine growth restriction
> Pregnant women with untreated epilepsy are not at increased risk of having a baby with a birth defect

Pre-pregnancy care

> In order to enable informed decisions and choice, and to reduce misunderstandings, women with epilepsy and their partners, as appropriate, must be given accurate information and counselling about
  > Contraception
  > Conception
  > Pregnancy
  > Caring for their baby and breastfeeding

Contraception

> Advise all women with epilepsy of childbearing age that the risk of failure of oral contraceptive agents is increased several-fold if they are taking an enzyme-inducing antiepileptic drug (e.g. phenobarbital, phenytoin, carbamazepine, or primidone)

Conception

> Pre-pregnancy counselling should provide a clear understanding of the risks of uncontrolled seizures and the possible teratogenicity of anticonvulsant agents
  > For women taking sodium valproate pre-pregnancy, consideration should be given to a suitable alternative agent if appropriate
> Most experts currently recommend high dose folic acid for women taking antiepileptic medication i.e. 5mg / day (10 times the prophylactic dose) for 1 month before conception and continue during the first trimester
> Genetic counselling is required if both parents have epilepsy or the disease is inherited
> Aim for seizure control at least 6 months before conception and, if possible, cease or use the lowest effective dose of a single anticonvulsant according to the type of epilepsy
If anticonvulsant drugs are required aim to achieve levels in the therapeutic range before conception.

**Pregnancy**

- Arrange review by a neurologist or specialist physician
- Obtain complete blood picture and serum folate levels
- Explain the importance of continuing anticonvulsant medication when this is necessary because of the maternal and fetal risks associated with convulsions
- Women should be re-assured that there is no evidence that simple partial, complex partial, absence and myoclonic seizures affect the pregnancy or developing fetus adversely unless they fall and sustain an injury.

**Antiepileptic drugs (AEDs)**

In Australia, the following commonly used antiepileptic drugs have been available for 20 years:

- Carbamazepine (ADEC Cat D)
- Clonazepam (ADEC Cat C)
- Ethosuximide (ADEC Cat D)
- Phenobarbitone (ADEC Cat D)
- Phenytoin (ADEC Cat D)
- Primidone (ADEC Cat D)
- Sodium valproate (ADEC Cat D)
- Sulthiame (ADEC Cat D)

In recent years new antiepileptic drugs have been released:

- Gabapentin (ADEC Cat B1)
- Lacosamide (ADEC Cat B3)
- Lamotrigine (ADEC Cat D)
- Levetiracetam (ADEC Cat B3)
- Oxcarbazepine (ADEC Cat D)
- Pregabalin (ADEC Cat B3)
- Tiagabine (ADEC Cat B3)
- Topiramate (ADEC Cat D)
- Vigabatrin (ADEC Cat D)
- Zonisamide (ADEC Cat D)

The following drugs are enzyme-inducing antiepileptic drugs:

- Carbamazepine
- Oxcarbazepine
- Phenobarbitone
- Phenytoin
- Primidone
- Topiramate

**Phenytoin**

- Narrow therapeutic window
- Increased clearance rate during pregnancy, leading to decreased serum concentrations
- Fall in total serum phenytoin concentrations may lead to poor seizure control
- Consideration should be given to monitoring phenytoin levels\(^1\)
- Associated major malformations are facial clefts, congenital heart defects and urogenital defects
Epilepsy and pregnancy management

> Associated with Fetal Hydantoin Syndrome (FHS) in 10% of exposed fetuses (dysmorphic facies and other features, distal phalangeal hypoplasia, abnormal growth and mental/motor development)12

**Carbamazepine**

> Large peak-trough fluctuations can be minimised by using a controlled-release formulation10, but this may require higher doses
> Pregnancy may cause a small decrease in the concentration of carbamazepine; consideration should be given to monitoring levels11
> Associated with major malformations including neural tube defects in up to 1% of exposed pregnancies, heart defects, inguinal hernia, hypospadias and hip dislocations
> Craniofacial abnormalities and developmental delay have been associated in some but not all studies with the use of carbamazepine both alone or with other anticonvulsants9,12

**Sodium valproate**

> Divided doses are preferred to avoid high peaks in serum concentrations
> Therapeutic range not closely correlated with efficacy – drug level monitoring is of limited value apart from suspected toxicity or non-compliance
> Exposure to valproate during early pregnancy is associated with a 1 to 2% incidence of neural tube defects, especially with doses > 1,000 mg/day
> Other defects include cardiovascular complications, urogenital malformations, skeletal defects; and facial dysmorphic patterns
> Large studies have produced an estimate of the incidence of congenital malformations in children exposed to valproic acid during pregnancy ranging from 5 to 18%12
> Emerging evidence suggests that valproate exposure in pregnancy may lead to neurodevelopmental delay (including decreased mental development, intelligence quotient (IQ) and cognition, and autism spectrum disorder)12

**Phenobarbital and Primidone**

> Barbiturates are now less frequently prescribed due to their tendency to produce sedation and impaired cognitive function
> Associated with congenital heart defects and facial clefts
> Infants born after exposure to phenobarbitone or primidone in utero should be monitored for withdrawal symptoms for up to 6 weeks after birth

**Lamotrigine**

> Lamotrigine clearance may be increased in pregnancy, leading to a reduction in lamotrigine concentrations and potential loss of seizure control11
> Lamotrigine levels should be monitored in pregnancy and the dose adjusted accordingly11
> To date data suggest that lamotrigine has not been shown to increase the risk of major birth defects, however there are conflicting reports of an association with the increased risk of oral facial clefts12

**New antiepileptic drugs**

> Gabapentin, lamotrigine, levetiracetam and vigabatrin have no antifolate effects8
> To date there has been no evidence of an increased incidence of major malformations with most of the newer antiepileptic drugs, although data are limited5,13
> Topiramate has been changed from ADEC category B3 to category D after inconsistent reports of an increased risk in facial clefts12
Management


Antenatal

> Physician / neurology review in each trimester
> Document history of seizure activity
> Maternal serum screening for alpha-fetoprotein at 14 – 20+6 weeks
> Offer first trimester combined screening for aneuploidy with detailed early morphology
  > Ensure the request form for obstetric ultrasound includes details of all antiepileptic drugs the woman is taking
> Detailed ultrasound assessment of the fetus at 18 – 20 weeks gestation (looking particularly for heart, renal and neural tube defects)
  > Ensure the request form for obstetric ultrasound includes details of all antiepileptic drugs the woman is taking
> Monitor plasma anticonvulsant levels (not useful for valproate) every 1 to 2 months. If there is deterioration in seizure control, adjust dose accordingly
> Women should be advised about the importance of proper sleep and medication compliance, particularly in the last trimester, when AED levels tend to be lowest
> Women should be encouraged to participate in the Australian Pregnancy Register for Women on Antiepileptic Drugs: tel: 1800 069 722

Vitamin K1

> Enzyme inducing antiepileptic drugs:
  > Carbamazepine
  > Oxcarbazepine
  > Phenobarbitone
  > Phenytoin
  > Primidone
  > Topirimate

are known to cross the placenta and promote oxidative degradation of vitamin K1 in the fetus
> Consider antenatal prophylaxis with oral vitamin K1 20 mg per day in the last 4 weeks of pregnancy if enzyme-inducing drugs are used (Konakion® MM ampoules 10 mg / 1 mL have Therapeutic Goods Administration [TGA] approval for oral use)
> If vitamin K1 has not been given antenatally, administer intravenous vitamin K1 10 mg by slow injection over 5 minutes in labour or threatened preterm labour

Intrapartum

> Most women with epilepsy will have a normal uncomplicated vaginal birth
> Two to four percent of women with epilepsy will have a tonic-clonic seizure during labour or in the first 24 hours after labour (see management in seizures in pregnancy)
> Tonic clonic seizures may result in fetal hypoxia
> Birth should be arranged in a hospital with facilities for emergency caesarean section and maternal and neonatal resuscitation
> Continue oral anticonvulsants
> Ensure intravenous access
> Paediatrician / neonatologist at birth

NOTE: Phenytoin and phenobarbitone are the only parenteral antiepileptics
> Women will not usually need parenteral anticonvulsants in labour unless they are vomiting and unable to take their usual anti-convulsant medication
> Women who have missed their anticonvulsant doses for more than 12 hours may need a parenteral dose. Consult a physician or neurologist.
Epilepsy and pregnancy management

> For women already on oral phenytoin, continue the same dose intravenously (divided doses)
> If the woman is on a different anticonvulsant, she will require a phenytoin loading dose (15 – 20 mg / kg) followed by maintenance doses of 8 mg / kg / day, approximately 300 mg, twice daily intravenously or orally
> Intravenous diazepam 5-10 mg can be used for acute seizure management in women on other anti-epileptic drugs (see management of seizures in seizures in pregnancy

Immediately following birth

> Advise the mother that intramuscular vitamin K1 should be administered to the newborn immediately after birth, and is the preferred method
  > 1 mg for term babies
  > 0.5 mg for babies < 1.5 kg bodyweight
> If vitamin K1 is preferred by the mother to be given orally, administer 3 doses of 2
  > Give first dose immediately following birth
  > Second dose on day three to five
  > Last dose at four weeks
> Observe baby closely for signs of respiratory depression
> Examine baby for signs of anticonvulsant and epilepsy-associated dysmorphology

Postpartum

Antiepileptic drugs

> Continue antiepileptic drugs
> Antiepileptic serum levels quickly revert to pre-pregnancy levels. Lamotrigine levels may increase and the dose will most likely need to be reduced

Newborn care

> Some antiepileptic drugs (e.g. phenobarbitone and primidone) can result in drug accumulation in the newborn
> Observe baby for level of alertness and signs of excessive drowsiness (may need to review breastfeeding)
> Valproate may be associated with jitteriness
> If maternal seizure control is poor there may be a risk of injury to the infant

Breastfeeding

> As antiepileptic drugs are excreted in breast milk only in low concentrations encourage breastfeeding
> If the mother is using antiepileptic drugs that are associated with drowsiness, monitor the breastfed baby for prolonged sedation, disinterest in feeding and inadequate weight gain, and ensure the mother is informed of safe sleeping practices
> **Lamotrigine requires caution** –If a rash occurs in the baby, breastfeeding should be ceased and the cause of the rash urgently established.
> For further information regarding antiepileptic drugs in breastfeeding contact the WCHN Medicines and Drug Information Centre – 08 8161 7222 Mon- Fri

Contraception

> The oral progestogen-only pill or progesterone implant (Implanon®) is unreliable contraception for women on the enzyme-inducing anticonvulsants
  > Carbamazepine
  > Oxcarbazepine
  > Phenobarbitone
Epilepsy and pregnancy management

> Phenytoin
> Primidone
> Topiramate

but acceptable for women on the others with the exception of lamotrigine

> Lamotrigine: Combined oral contraceptives may increase lamotrigine’s metabolism, decreasing its concentration and efficacy (during the week when inactive combined oral contraceptive sugar pill is taken lamotrigine’s concentration may rise); consider using an alternative contraceptive; contact one of the pregnancy drug information centres (AMH)

> Medroxyprogesterone acetate depot injection can be used and most guidance suggests shortening the usual 12 weeks interval to 10 weeks for women taking enzyme-inducing AEDs

> Levonorgestrel IUD (Mirena) is also a useful contraceptive in these circumstances

> Sequential pills or combined pills containing less than 50 micrograms of oestrogen may be associated with an increased incidence of breakthrough bleeding, or contraceptive failure, and should be avoided

> Women taking enzyme-inducing AEDs and the combined oral contraceptive should be advised:

> To take at least 50 micrograms of ethinyloestradiol (e.g. Microgynon 50) and to report any breakthrough bleeding. If breakthrough bleeding occurs the dose of ethinyloestradiol can be increased to 80 – 100 micrograms

Discharge counselling

> Offer advice to women at risk of further seizure activity to minimise any injury risk to baby:

> Feed baby seated low or on floor
> Bath baby with another person present whenever possible
> Minimise carrying of baby
> Use a pram with an automatic brake

Follow up

> Arrange neurological or general practitioner follow up before discharge
References

3. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052 922 and age-specific fertility rates of women with epilepsy (Level III-2).

Useful web sites

Epilepsy and pregnancy management

Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

**Write Group Lead**
Dr Mark Morton

**Write Group Members**
Allison Rogers
Dr Brian Peat
Neil Hotham

**Other major contributors**
Jill Phelps
Catherine Leggett
Dr Bill Hague
Dr Bill Jeffries
Dr Elinor Atkinson

**SAPPG Management Group Members**
Sonia Angus
Dr Kris Bascomb
Lyn Bastian
Elizabeth Bennett
Dr Feisal Chenia
John Coomblas
A/Prof Rosalie Grivell
Dr Sue Kennedy-Andrews
Jackie Kitschke
Catherine Leggett
Dr Anupam Parange
Dr Andrew McPhee
Rebecca Smith
A/Prof John Svigos
Dr Laura Willington
Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: HealthCYWHSPerinatalProtocol@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 31 December 2019
ISBN number: 978-1-74243-067-6
PDS reference: CG185
Policy history:

Is this a new policy (V1)? N
Does this policy amend or update an existing policy? Y
If so, which version? V4
Does this policy replace another policy with a different title? N
If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 Jun 2018</td>
<td>V4.1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Review date extended to 5 years following risk assessment. New template.</td>
</tr>
<tr>
<td>19 Dec 2014</td>
<td>V4</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed in line with scheduled review date.</td>
</tr>
<tr>
<td>08 Jan 2013</td>
<td>V3</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>15 Dec 2008</td>
<td>V2</td>
<td>Maternal and Neonatal Clinical Network</td>
<td>Reviewed in line with scheduled review date.</td>
</tr>
</tbody>
</table>